Translational Role of Internal Medicine in Advancing Pediatric Precision Medicine
Abstract
Precision medicine is rapidly gaining traction in pediatrics. Although traditionally associated with adult care, internal medicine has become an essential contributor to the advancement of precision approaches for young patients. The growing overlap between internal medicine and pediatrics lies in translational research, technological innovation, and collaborative subspecialty care. Internal medicine has played a key role in developing genomic, proteomic, and bioinformatic tools that now underpin pediatric precision medicine. These advances enable clinicians to identify children at high risk for specific diseases, predict disease trajectories, and select the most effective therapies with minimal side effects. This review examines the evolving landscape of pediatric precision medicine, emphasizing how internal medicine research and interspecialty collaboration drive innovation in pediatric diagnostics and therapeutics. By analyzing current research and clinical practices, we aim to clarify the translational and collaborative role of internal medicine in delivering personalized care to children.
Get full access to this article
View all access and purchase options for this article.
Data availability statement
Not applicable.
References
1. Dimitri P. Precision diagnostics in children. Camb Prism Precis Med. 2023;1:e17.
2. Al-Dewik NI, Younes SN, Essa MM, Pathak S, Qoronfleh MW. Making biomarkers relevant to healthcare innovation and precision medicine. Processes. 2022;10(6):1107.
3. Elzagallaai A, Barker C, Lewis T, Cohn R, Rieder M. Advancing precision medicine in paediatrics: past, present and future. Camb Prism Precis Med. 2023;1:e11.
4. Dhoundiyal S, Srivastava S, Kumar S, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. Eur J Med Res. 2024;29(1):26.
5. Leslie LK, Orr CJ, Turner AL, et al. Child health and the US pediatric subspecialty workforce: planning for the future. Pediatrics. 2024;153(suppl 2):e2023063678B.
6. Waters A, Lemaire M. Molecular diagnosis of genetic diseases of the kidney: primer for pediatric nephrologists. In: Schaefer F, Greenbaum LA, eds. Pediatric Kidney Disease. Cham: Springer; 2023:119-169.
7. Bassareo PP, Chessa M, Di Salvo G, Walsh KP, Mcmahon CJ. Strategies to aid successful transition of adolescents with congenital heart disease: a systematic review. Children. 2023;10(3):423.
8. Liu Q, Li C, Yang L, et al. Weight status change during four years and left ventricular hypertrophy in Chinese children. Front Pediatr. 2024;12:1371286.
9. Zhou Y, Li L, Yu Z, et al. Dermatophagoides pteronyssinus allergen Der p 22: cloning, expression, IgE-binding in asthmatic children, and immunogenicity. Pediatr Allergy Immunol. 2022;33(8):e13835.
10. Hopkins K, Dziedzic C, Qadir A, et al. Guidelines in pediatric cardiology. In: Abdulla R-i, Berger S, Backer C, et al., eds. Pediatric Cardiology: Fetal, Pediatric, and Adult Congenital Heart Diseases. Cham: Springer; 2024:2919-3010.
11. Khoja A, Andraweera PH, Lassi ZS, et al. Risk factors for early versus late-onset coronary heart disease (CHD): systematic review and meta-analysis. Heart Lung Circ. 2023;32(11):1277-1311.
12. Al-Obaidi AD, Ali AM, Ahmad SS, Khalaf AKs Hashim AT, Mohammed MQ. Double Inlet Left Ventricle. In: Tagarakis G, Sarfan AG, Hashim HT, Varney J, eds. Clinical and Surgical Aspects of Congenital Heart Diseases: Text and Study Guide. Cham: Springer; 2023:155-164.
13. Vo CH, Bushman GA, Kleiman ZI, Quiñónez ZA, Kleiman ZI, Quiñónez ZA. Tetralogy of Fallot. In: Dabbagh A, Conte AH, Lubin LN, eds. Congenital Heart Disease in Pediatric and Adult Patients: Anesthetic and Perioperative Management. Cham: Springer; 2023:437-468.
14. Yasuhara J, Garg V. Genetics of congenital heart disease: a narrative review of recent advances and clinical implications. Transl Pediatr. 2021;10(9):2366-2386.
15. Bragança J, Pinto R, Silva B, Marques N, Leitão HS, Fernandes MT. Charting the path: navigating embryonic development to potentially safeguard against congenital heart defects. J Pers Med. 2023;13(8):1263.
16. Khoury MJ, Bowen S, Dotson WD, et al. Health equity in the implementation of genomics and precision medicine: a public health imperative. Genet Med. 2022;24(8):1630-1639.
17. Newland DM, Law YM, Albers EL, et al. Early clinical experience with dapagliflozin in children with heart failure. Pediatr Cardiol. 2023;44(1):146-152.
18. Laeer S, Cawello W, Burckhardt BB, et al. Enalapril and enalaprilat pharmacokinetics in children with heart failure due to dilated cardiomyopathy and congestive heart failure after administration of an orodispersible enalapril minitablet (LENA-Studies). Pharmaceutics. 2022;14(6):1163.
19. Haddad CN, Ali S, Stephanou D, Assakura MS, Sahagian L, Trogkanis E. Pharmacological management of dilated cardiomyopathy in Duchenne muscular dystrophy: a systematic review. Hellenic J Cardiol. 2023;74:58-64.
20. Townsend M, Jeewa A, Khoury M, Cunningham C, George K, Conway J. Unique aspects of hypertrophic cardiomyopathy in children. Can J Cardiol. 2024;40(5):907-920.
21. Walton M, Wagner JB. Pediatric beta blocker therapy: a comprehensive review of development and genetic variation to guide precision-based therapy in children, adolescents, and young adults. Genes. 2024;15(3):379.
22. Wagner D, Kronick S, Nawer H, Cranford J, Bradley S, Neumar R. Comparative effectiveness of amiodarone and lidocaine for the treatment of in-hospital cardiac arrest. Chest. 2023;163(5):1109-1119.
23. Batra AS, Silka MJ, Borquez A, et al. Pharmacological management of cardiac arrhythmias in the fetal and neonatal periods: a scientific statement from the American Heart Association. Circulation. 2024;149(10):e937-e952.
24. Ferguson MA, Stein DR. Pharmacologic treatment of pediatric hypertension. In: Flynn JT, Ingelfinger JR, Brady TM, eds. Pediatric Hypertension. Cham: Springer; 2023:857-881.
25. Xu Y, Zhang M, Chen Y, et al. Does sacubitril/valsartan work in children with heart failure?—a pilot study. Front Cardiovasc Med. 2023;10:1274990.
26. Moran C, Schoenmakers N, Halsall D, et al. Approach to the patient with raised thyroid hormones and nonsuppressed TSH. J Clin Endocrinol Metab. 2024;109(4):1094-1108.
27. Rose SR, Wassner AJ, Wintergerst KA, et al. Congenital hypothyroidism: screening and management. Pediatrics. 2023;151(1):e2022060419.
28. Klein KO, Mauras N, Nayak S, et al. Efficacy and safety of leuprolide acetate 6-month depot for the treatment of central precocious puberty: a phase 3 study. J Endocr Soc. 2023;7(7):bvad071.
29. Bizzarri C, Capalbo D, Wasniewska MG, Baronio F, Grandone A, Cappa M. Adrenal crisis in infants and young children with adrenal insufficiency: management and prevention. Front Endocrinol (Lausanne). 2023;14:1133376.
30. Tlemsani C, Larousserie F, De Percin S, et al. Biology and management of high-grade chondrosarcoma: an update on targets and treatment options. Int J Mol Sci. 2023;24(2):1361.
31. Nur Sunar Yayla E, Yıldız Ç, Esmeray Şenol P, Karaçayır N, Gezgin Yıldırım D, Bakkaloğlu SA. How safe are biological agents in pediatric rheumatology. Turk Arch Pediatr. 2024;59(2):185-192.
32. Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603-5607.
33. Ramanan AV, Quartier P, Okamoto N, et al. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial. Lancet. 2023;402(10401):555-570.
34. Chang C, Vong C, Wang X, et al. Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis. CPT Pharmacometrics Syst Pharmacol. 2024;13(4):599-611.
35. Lin T-W, Lin Y-T, Hu Y-C, Yu H-H, Chiang B-L. Rituximab as an effective add-on maintenance therapy for disease activities in childhood-onset systemic lupus erythematosus. Lupus Sci. Med. 2024;11(1):e000987.
36. Kontaki E, Merchant A, Gaynor E, Kiparissi F. P494 Efficacy and safety of Upadacitinib in moderate to severe paediatric Crohn’s disease and ulcerative colitis in a tertiary Paediatric IBD (PIBD) centre: a case series. J Crohns Colitis. 2024;18(suppl_1):i986-i986.
37. Lee S, Yang MH, Kim JS, et al. Evaluation of off-label medication use and drug safety in a pediatric intensive care unit. Saudi Pharm J. 2023;31(9):101704.
38. Savage MO, Donaldson MD, Davies JH, Storr HL. Key stages in the development and establishment of padiatric endocrinology: a template for feature progress. Horm Res Paediatr. 2024;97:22-27.
39. Davies K. Care of children and young people with endocrine problems. Nurs Child Young People. 2017:328. https://openresearch.lsbu.ac.uk/item/8q8w9.
40. Orçun A, Yildiz Z, Köroğlu Dağdelen L. Pediatric reference intervals for free testosterone, 17-OH progesterone, androstenedione, and IGF-1 with chemiluminescence immunoassay. Steroids. 2022;186:109078.
41. O’Connell MA, Atlas G, Ayers K, Sinclair A. Establishing a molecular genetic diagnosis in children with differences of sex development: a clinical approach. Horm Res Paediatr. 2023;96(2):128-143.
42. Hanafy AK, Mujtaba B, Roman-Colon AM, et al. Imaging features of adrenal gland masses in the pediatric population. Abdom Radiol (NY). 2020;45(4):964-981.
43. Ergun-Longmire B, Rowland D, Dewey J, Vining-Maravolo P. A narrative review: an update on primary adrenal insufficiency (PAI) in pediatric population. Pediatr Med. 2023;30:6.
44. Sipos JA, Ringel MD. Molecular testing in thyroid cancer diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2023;37(1):101680.
45. Sahakian N, Castinetti F, Romanet P, Reznik Y, Brue T. Updates on the genetics of multiple endocrine neoplasia. Ann Endocrinol (Paris). 2024;85(2):127-135.
46. Gippert S, Wagner M, Brunet T, et al. Exome sequencing (ES) of a pediatric cohort with chronic endocrine diseases: a single-center study (within the framework of the TRANSLATE-NAMSE project). Endocrine. 2024;85(1):444-453.
47. Gupta A, Aggarwal A. Pediatric rheumatology: the last bastion of pediatrics. Indian J Pediatr. 2024;91(9):919-920.
48. Reiff DD, Bridges JM, Rife EC, et al. Majority of new patient referrals to a large pediatric rheumatology center result in non-rheumatic diagnosis. Pediatr Rheumatol. 2023;21(1):120.
49. Gibson K. Assessment of Biological Markers to Aid Subtype Classification in Pediatric Primary Systemic Vasculitis. University of British Columbia; September 6, 2023. Accessed May 13, 2025. https://open.library.ubc.ca/media/stream/pdf/24/1.0435766/3.
50. García B, Pesántez M, Carbaca V, et al. Systemic lupus erythematosus: update on the diagnosis, prevalence, clinical management, inflammatory markers, new horizons in the pathogenesis, manifestations, and progress in treatment. EPRA Int J Multidiscip Res. 2024:317-325.
51. de Sousa RN, Tascilar K, Corte G, et al. Metabolic and molecular imaging in inflammatory arthritis. RMD Open. 2024;10(1):e003880.
52. Moltrasio C, Romagnuolo M, Marzano AV. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: from cryopyrin function to targeted therapies. Front Immunol. 2022;13:1007705.
53. Gray PE, David C. Inborn errors of immunity and autoimmune disease. J Allergy Clin Immunol Pract. 2023;11(6):1602-1622.
54. Foeldvari I, Torok KS, Antón J, et al. Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance-the result of the International Hamburg Consensus Meeting December 2022. Expert Rev Clin Immunol. 2024;20(4):387-404.
55. Sharma S, Basu S, Goyal RK, Sahoo PK, Mathur R. Rituximab, a safer option for rheumatoid arthritis: a comparison of the reported adverse events of approved monoclonal antibodies. J Pharmacol Pharmacother. 2022;13(4):330-340.
56. Han GT, Heavner HS, Rains TR, Hoang AH, Stone AL. Chronic pain in autistic youth: clinical prevalence and reflections on tailoring evidence-based interventions from an Interdisciplinary Treatment Team. Children. 2024;11(3):312.
57. Lerner DG, Mencin A, Novak I, et al. Advances in pediatric diagnostic endoscopy: a state-of-the-art review. JPGN Rep. 2022;3(3):e224.
58. Sauer CG, Barnard JA, Vinci RJ, Strople JA. Child health needs and the pediatric gastroenterology workforce: 2020–2040. Pediatrics. 2024;153(suppl 2):e2023063678K.
59. Harrold EC, Stadler ZK. Upper gastrointestinal cancers and the role of genetic testing. Hematol Oncol Clin North Am. 2024;38(3):677-691.
60. Votto M, Naso M, Brambilla I, et al. Eosinophilic gastrointestinal diseases in inborn errors of immunity. J Clin Med. 2023;12(2):514.
61. Wenzel A, Gold BD, Strople J. Laboratory evaluation of inflammatory bowel disease. Pediatr Inflamm Bowel Dis. 2023:229-244.
62. Kim JH, Yi DY, Lee YM, et al. Association between body mass index and fecal calprotectin levels in children and adolescents with irritable bowel syndrome. Medicine. 2022;101(32):e29968.
63. Muralinath E, Prasad MG, Sharlet S. Clinical Review Articles in Physio Pharmacology. Solapur, India: Laxmi Book Publication; 2024.
64. Trubicka J, Grajkowska W, Dembowska-Bagińska B. Molecular markers of pediatric solid tumors—diagnosis, optimizing treatments, and determining susceptibility: current state and future directions. Cells. 2022;11(7):1238.
65. Freedman JL, Beeler DM, Bowers A, et al. Supportive care in pediatric oncology: opportunities and future directions. Cancers. 2023;15(23):5549.
66. Pankiw M, Brezden-Masley C, Charames GS. Comprehensive genomic profiling for oncological advancements by precision medicine. Med. Oncol. 2023;41(1):1.
67. Lejman M, Chałupnik A, Chilimoniuk Z, Dobosz M. Genetic biomarkers and their clinical implications in B-cell acute lymphoblastic leukemia in children. Int J Mol Sci. 2022;23(5):2755.
68. Fang FY, Rosenblum JS, Ho WS, Heiss JD. New developments in the pathogenesis, therapeutic targeting, and treatment of pediatric medulloblastoma. Cancers. 2022;14(9):2285.
69. Rulten SL, Grose RP, Gatz SA, Jones JL, Cameron AJ. The future of precision oncology. Int J Mol Sci. 2023;24(16):12613.
70. Falaschi Z, Giaconi C, Fanni SC, et al. Multimodality imaging of pediatrics tumors. In: Neri E, Erba PA, eds. Multimodality Imaging and Intervention in Oncology. Cham: Springer; 2023:513-549.
71. Pokorna P, Palova H, Adamcova S, et al. Real-world performance of integrative clinical genomics in pediatric precision oncology. Lab Invest. 2024;104(12):102161.
72. Simon J, Reita D, Guerin E, et al. Clinical impact of large genomic explorations at diagnosis in 198 pediatric solid tumors: a monocentric study aiming practical feasibility of precision oncology. BMC Cancer. 2024;24(1):1296.
73. Larrosa C, Mora J, Cheung N-K. Global impact of monoclonal antibodies (mAbs) in children: a focus on anti-GD2. Cancers. 2023;15(14):3729.
74. Terry RL, Meyran D, Fleuren ED, et al. Chimeric antigen receptor T cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma. Cancers. 2021;13(18):4704.
75. Lee WG, Kim ES. Precision oncology in pediatric cancer surgery. Surg Oncol Clin N Am. 2024;33(2):409-446.
76. Fahmy SA, Dawoud A, Zeinelabdeen YA, et al. Molecular engines, therapeutic targets, and challenges in pediatric brain tumors: a special emphasis on hydrogen sulfide and RNA-based nano-delivery. Cancers. 2022;14(21):5244.
77. Yao Q, Gorevic P, Shen B, Gibson G. Genetically transitional disease: a new concept in genomic medicine. Trends Genet. 2023;39(2):98-108.
78. Hasadsri L, Allyse MA. Noninvasive prenatal screening for fetal aneuploidies. In: Coleman WB, Tsongalis GJ, eds. Diagnostic Molecular Pathology. Amsterdam: Elsevier; 2024:217-229.
79. Piñero J, Rodriguez Fraga PS, Valls-Margarit J, et al. Genomic and proteomic biomarker landscape in clinical trials. Comput Struct Biotechnol J. 2023;21:2110-2118.
80. Mittal AK, Shekhawat DS, Joshi V, Singh P, Singh K. Next-generation sequencing in newborn screening: a review on clinical and economic prospects. Open Biotechnol J. 2023;17(1):20226.
81. Rudowski S, Boerkoel CF, He M, Kanungo S. Whole genome sequencing in era of newborn screening. OBM Genetics. 2023;7(4):1-19. https://www.lidsen.com/journals/genetics/genetics-07-04-195.
82. Mustafa AS. Whole genome sequencing: applications in clinical bacteriology. Med Princ Pract. 2024;33(3):185-197.
83. D’Gama AM, Agrawal PB. Genomic medicine in neonatal care: progress and challenges. Eur J Hum Genet. 2023;31(12):1357-1363.
84. Edsjö A, Gisselsson D, Staaf J, et al. Current and emerging sequencing-based tools for precision cancer medicine. Mol Aspects Med. 2024;96:101250.
85. Fasaludeen A, McTague A, Jose M, et al. Genetic variant interpretation for the neurologist-A pragmatic approach in the next-generation sequencing era in childhood epilepsy. Epilepsy Res. 2024:107341.
86. Alimohamed MZ, Siima AA, Manji M. Advancing genetic testing for neurological disorders in Tanzania: importance, challenges, and strategies for implementation. Front Neurosci. 2024;18:1371372.
87. Hosseini SY, Mallick R, Mäkinen P, Ylä-Herttuala S. Navigating the prime editing strategy to treat cardiovascular genetic disorders in transforming heart health. Expert Rev Cardiovasc Ther. 2024;22(1-3):75-89.
88. Ahmad A, Imran M, Ahsan H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel Biomarkers of diseases. Pharmaceutics. 2023;15(6):1630.
89. Watanabe H, Nagano N, Tsuji Y, Noto N, Ayusawa M, Morioka I. Challenges of pediatric pharmacotherapy: a narrative review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Eur J Clin Pharmacol. 2024;80(2):203-221.
90. Tao R, Han X, Bai X, et al. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology. Front Immunol. 2024;15:1354825.
91. Elliott AM. Genetic counseling and genome sequencing in pediatric rare disease. Cold Spring Harb Perspect Med. 2020;10(3):a036632.
92. French CE, Andrews NC, Beggs AH, et al. Hospital-wide access to genomic data advanced pediatric rare disease research and clinical outcomes. Npj Genom Med. 2024;9(1):60.
93. Sullivan JA, Schoch K, Spillmann RC, Shashi V. Exome/genome sequencing in undiagnosed syndromes. Annu Rev Med. 2023;74(1):489-502.
94. Singla A. Precision medicine: tailoring treatment to individual genetic profiles. Shodh Sagar Journal for Medical Research Advancement. 2024;1(1):27-37.
95. Marques L, Costa B, Pereira M, et al. Advancing precision medicine: a review of innovative In Silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics. 2024;16(3):332.
96. van Groen BD, Allegaert K, Tibboel D, de Wildt SN. Innovative approaches and recent advances in the study of ontogeny of drug metabolism and transport. Br J Clin Pharmacol. 2022;88(10):4285-4296.
97. Yalçin N, Flint RB, van Schaik RHN, Simons SHP, Allegaert K. The impact of pharmacogenetics on pharmacokinetics and pharmacodynamics in neonates and infants: a systematic review. Pharmgenomics Pers Med. 2022;15:675-696.
98. Bonilha AE. Sequencing the baby’s genome: ethical and policy considerations for genetic counselors in newborn screening programs. McGill University (Canada); August 2023. Accessed March 29, 2025. https://escholarship.mcgill.ca/concern/theses/sf268b889.
99. Parker LS. Ethical considerations in precision medicine. In: Bydon M, eds. The New Era of Precision Medicine. Amsterdam: Elsevier; 2024:143-172.
100. Sarwar E. Global Perspectives on Precision Medicine: Ethical, Social and Public Health Implications. Cham: Springer Nature; 2023.
101. Kariyawasam DS, Scarfe J, Meagher C, et al. Integrating ethics and equity with economics and effectiveness for newborn screening in the genomic age: a qualitative study protocol of stakeholder perspectives. PLoS ONE. 2024;19(3):e0299336.
102. Subasri M, Cressman C, Arje D, et al. Translating precision health for pediatrics: a scoping review. Children. 2023;10(5):897.
103. Prabhakar PK. Biomedical Research Developments for Improved Healthcare. Hershey, PA: IGI Global; 2024.
104. Papadopoulou P, Lytras M. Advancing precision medicine in medical education: integrated, precise and data-driven smart solutions. Appl Res. 2023;2(6):e202200131.
105. Yan H, Bytautas J, Isenberg SR, et al. Grief and bereavement of family and friends around medical assistance in dying: scoping review. BMJ Support Palliat Care. 2023;13(4):414-428.
106. Forde J. The Irish Early Childhood Care and Education (ECCE) scheme is free and universal, but at whose expense?, 2022. Accessed May 25, 2025. https://sword.mtu.ie/allthe/541/.
Cite
Cite
Cite
OR
Download to reference manager
If you have citation software installed, you can download citation data to the citation manager of your choice
Information, rights and permissions
Information
Published In
Article first published online: April 10, 2026
Keywords
Data availability statement
Data is available for this article. View more information
PubMed: 41964150
Authors
Metrics and citations
Metrics
Publication usage*
Total views and downloads: 0
*Publication usage tracking started in December 2016
Publications citing this one
Receive email alerts when this publication is cited
Web of Science: 0
Crossref:
There are no citing articles to show.
Figures and tables
Figures & Media
Tables
View Options
Access options
If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below:
I am signed in as:
View my profileSign out
I can access personal subscriptions, purchases, paired institutional access and free tools such as favourite journals, email alerts and saved searches.
loading institutional access options
Alternatively, view purchase options below:
Purchase 24 hour online access to view and download content.
Access journal content via a DeepDyve subscription or find out more about this option.
